Welcome to our dedicated page for QTMM news (Ticker: QTMM), a resource for investors and traders seeking the latest updates and insights on QTMM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QTMM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QTMM's position in the market.
Quantum Materials Corp (QTMM) announced progress regarding its trading status and SEC actions. The SEC suspended trading on May 12, 2021, due to the company failing to file required reports, which led to shares trading only on the Expert Market. Quantum intends to regain its reporting issuer status and will seek shareholder approval for an amendment to increase authorized shares to raise capital. The company reports advancements in point of care testing technologies and solar solutions but acknowledges challenges from COVID-19 affecting its operations.
Quantum Materials Corp (QTMM) issued a press release addressing the 10-day suspension of trading due to unmet reporting obligations. The Securities and Exchange Commission halted trading from May 13 to May 26, 2021. Currently, shares are traded only on the Expert Market, with no public quotes available. The company has retained legal counsel for compliance and is working to address SEC issues while continuing development in quantum dot technologies.
Quantum Materials Corp (OTCQB:QTMM) announced the temporary suspension of its common stock trading due to a lack of current information following the failure to file certain periodic reports. The suspension started at 9:30 AM on May 13, 2021, and is set to end at 11:59 PM on May 26, 2021. The SEC has initiated administrative proceedings regarding the company's registration under the Securities Exchange Act of 1934. Despite past delinquency since 2019, the company is making efforts to regain compliance by filing overdue reports, but the timeline for resuming trading remains uncertain.
Quantum Materials Corp has announced that its subsidiary, QMC HealthID, will be featured at the Materials Research Society (MRS) Virtual Spring Meeting 2021. The event will showcase QMC’s nanomaterial solutions for COVID-19 testing and its blockchain-based anti-counterfeiting technology. The MRS meeting aims to foster interdisciplinary collaboration and disseminate key advancements in materials science. QMC’s focus on innovative health technologies positions it as a significant player in addressing global health challenges.
Quantum Materials Corp announced the deployment of its QMC HealthID™ software platform for voluntary COVID testing at the Les Victoires de la Musique awards in Paris. Collaborating with Innova Medical Group, the platform facilitated real-time verification and outcome notifications for participants undergoing rapid COVID-19 testing. The effort showcased a commitment to ensuring safe events and aligns with QMC's mission to support public health initiatives. The company emphasizes its role in overcoming global health challenges through innovation and technology.
Quantum Materials Corp (QMC) has appointed three new executives: Dr. John Carrano as Senior VP Clinical R&D and Regulatory Affairs, Pete Cona as COO, and Dr. Nicholas Vitalari as Chief Strategy Officer. Dr. Carrano, previously CEO of Paratus Diagnostics, brings extensive capital-raising experience in diagnostics. Cona has over 30 years in business management, while Vitalari transitions from an advisory role to focus on strategic initiatives. These appointments align with QMC's plans for its subsidiary, QMC HealthID, to leverage quantum dot technology in COVID-19 testing and point-of-care diagnostics.
Quantum Materials Corp's subsidiary, QMC HealthID, has forged a partnership with Tried & Tested to enhance COVID-19 testing services. This collaboration aims to streamline test selection and result recording using QMC HealthID technology. Tried & Tested specializes in diverse testing methods, including Antigen and PCR tests, leveraging its experience in large-scale program implementation. Both companies aim to combat COVID-19's impact while offering robust testing solutions in the UK market. CEO Stephen Squires emphasizes the partnership's potential to accelerate the rollout of QMC HealthID.
Quantum Materials Corp (OTCQB: QTMM) announced a $15 million equity investment from Pasaca Capital to boost its QMC HealthID™ solution and quantum dot technology in healthcare. Under their agreement, QMC will earn at least $15 million in royalties or revenues over a specified period, focused on developing advanced COVID-19 rapid test kits in collaboration with Innova Medical Group. CEO Stephen Squires emphasized the potential for innovation and collaboration between the companies to enhance healthcare diagnostics.
QDX HealthID, a subsidiary of Quantum Materials Corp. (QTMM), has been renamed QMC HealthID to strengthen ties with its parent company. The change aligns with advancements in quantum dot technology for COVID-19 testing, promising faster, easier, and more accurate results. To support growth, Dr. Todd K. Malan has been appointed as the new senior vice president of clinical research. He brings expertise in health diagnostics and applied biotechnology. The company aims to improve testing accuracy and combat counterfeit tests through its unique technology.
